These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16920253)

  • 21. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
    J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. REG1A predicts recurrence in stage Ta/T1 bladder cancer.
    Geng J; Fan J; Wang P; Fang ZJ; Xia GW; Jiang HW; Chen G; Ding Q
    Eur J Surg Oncol; 2009 Aug; 35(8):852-7. PubMed ID: 19167858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression.
    Lee ES; Son DS; Kim SH; Lee J; Jo J; Han J; Kim H; Lee HJ; Choi HY; Jung Y; Park M; Lim YS; Kim K; Shim Y; Kim BC; Lee K; Huh N; Ko C; Park K; Lee JW; Choi YS; Kim J
    Clin Cancer Res; 2008 Nov; 14(22):7397-404. PubMed ID: 19010856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma.
    Mengual L; Burset M; Ribal MJ; Ars E; Marín-Aguilera M; Fernández M; Ingelmo-Torres M; Villavicencio H; Alcaraz A
    Clin Cancer Res; 2010 May; 16(9):2624-33. PubMed ID: 20406841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
    Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential diagnosis and evaluation of the clinical course of transurethrally resected T1G3 urothelial carcinoma of the bladder by DNA image cytometry.
    Biesterfeld S; Borchers H; Jellouschek H; Bono AV; Altwein JE; Algaba F; Jakse G
    Anticancer Res; 2005; 25(5):3243-9. PubMed ID: 16101134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
    Jancke G; Damm O; Rosell J; Jahnson S
    Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survivin expression predicts early recurrence in early-stage breast cancer.
    Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
    Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
    Guney S; Guney N; Canogullari Z; Ergenekon E
    Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma.
    Smaldone MC; Jacobs BL; Smaldone AM; Hrebinko RL
    Urology; 2008 Sep; 72(3):613-6. PubMed ID: 18554696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy.
    Kreike B; Halfwerk H; Kristel P; Glas A; Peterse H; Bartelink H; van de Vijver MJ
    Clin Cancer Res; 2006 Oct; 12(19):5705-12. PubMed ID: 17020974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder.
    Holyoake A; O'Sullivan P; Pollock R; Best T; Watanabe J; Kajita Y; Matsui Y; Ito M; Nishiyama H; Kerr N; da Silva Tatley F; Cambridge L; Toro T; Ogawa O; Guilford P
    Clin Cancer Res; 2008 Feb; 14(3):742-9. PubMed ID: 18245534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of oncologic outcome of laparoscopic nephroureterectomy and standard nephroureterectomy for upper urinary tract transitional cell carcinoma.
    Manabe D; Saika T; Ebara S; Uehara S; Nagai A; Fujita R; Irie S; Yamada D; Tsushima T; Nasu Y; Kumon H;
    Urology; 2007 Mar; 69(3):457-61. PubMed ID: 17382144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infrequent microsatellite instability in urothelial cell carcinoma of the bladder in young patients.
    Mongiat-Artus P; Miquel C; van der Aa M; Buhard O; Hamelin R; Bangma C; Teillac P; van der Kwast T; Praz F
    Eur Urol; 2006 Apr; 49(4):685-90. PubMed ID: 16413104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy.
    Bruins HM; Huang GJ; Cai J; Skinner DG; Stein JP; Penson DF
    J Urol; 2009 Nov; 182(5):2182-7. PubMed ID: 19758623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
    Catto JW; Abbod MF; Linkens DA; Larré S; Rosario DJ; Hamdy FC
    Clin Cancer Res; 2009 May; 15(9):3150-5. PubMed ID: 19336522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.